These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25182505)

  • 21. Pathogenesis of haemophilic arthropathy.
    Roosendaal G; Lafeber FP
    Haemophilia; 2006 Jul; 12 Suppl 3():117-21. PubMed ID: 16684006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross sectional study to investigate the influence of treatment regimes on the development of haemophilic arthropathy.
    Hilberg T; Czepa D
    Hamostaseologie; 2009 Oct; 29 Suppl 1():S77-9. PubMed ID: 19763361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synovitis in a murine model of human factor VIII deficiency.
    Hakobyan N; Kazarian T; Valentino LA
    Haemophilia; 2005 May; 11(3):227-32. PubMed ID: 15876267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of Deferasirox for removal of cadmium ions in rat.
    Saljooghi AS; Fatemi SJ
    Biometals; 2010 Aug; 23(4):707-12. PubMed ID: 20401682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathology of synovitis and hemophilic arthropathy].
    Roosendaal G; van den Berg HM; Lafeber FP; Bijlsma J
    Orthopade; 1999 Apr; 28(4):323-8. PubMed ID: 10335526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knee arthropathy: when things go wrong.
    Solimeno L; Luck J; Fondanesche C; McLaughlin P; Narayan P; Sabbour A; Sohail T; Pasta G
    Haemophilia; 2012 Jul; 18 Suppl 4():105-11. PubMed ID: 22726092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score.
    Melchiorre D; Linari S; Innocenti M; Biscoglio I; Toigo M; Cerinic MM; Morfini M
    Haemophilia; 2011 Jan; 17(1):112-7. PubMed ID: 21070482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intra-articular injections of hyaluronic acid induce positive clinical effects in knees of patients affected by haemophilic arthropathy.
    Carulli C; Matassi F; Civinini R; Morfini M; Tani M; Innocenti M
    Knee; 2013 Jan; 20(1):36-9. PubMed ID: 22704969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-10 protects against blood-induced joint damage.
    Jansen NW; Roosendaal G; Hooiveld MJ; Bijlsma JW; van Roon JA; Theobald M; Lafeber FP
    Br J Haematol; 2008 Sep; 142(6):953-61. PubMed ID: 18637801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The musculoskeletal manifestations of haemophilia: a review of the imaging findings.
    Ray A; Colville JG; Hartley R; Rowbotham E
    Clin Radiol; 2022 Oct; 77(10):730-737. PubMed ID: 35985846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis of haemophilic synovitis: clinical aspects.
    Hoots WK; Rodriguez N; Boggio L; Valentino LA
    Haemophilia; 2007 Nov; 13 Suppl 3():4-9. PubMed ID: 17822514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferasirox--current knowledge and future challenges.
    Porter JB
    Ann N Y Acad Sci; 2010 Aug; 1202():87-93. PubMed ID: 20712778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
    Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
    Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.